Immune checkpoint inhibitors in cancer: the increased risk of atherosclerotic cardiovascular disease events and progression of coronary artery calcium.
Bingxin GongYusheng GuoYi LiJing WangGuofeng ZhouYong-Hao ChenTong NieMing YangKun LuoChuansheng ZhengFeng PanBo LiangLian YangPublished in: BMC medicine (2024)
Treatment with ICIs was associated with a higher rate of ASCVD events and a noticeable increase in CAC progression.